We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zomedica Pharmaceuticals Corp. (ZOM) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
In the latest trading session, Zomedica Pharmaceuticals Corp. (ZOM - Free Report) closed at $0.16, marking a +0.57% move from the previous day. This change lagged the S&P 500's 0.72% gain on the day. Meanwhile, the Dow gained 0.89%, and the Nasdaq, a tech-heavy index, added 1.47%.
Coming into today, shares of the company had lost 5.89% in the past month. In that same time, the Medical sector gained 3.7%, while the S&P 500 gained 5.85%.
Wall Street will be looking for positivity from ZOM as it approaches its next earnings report date. On that day, ZOM is projected to report earnings of -$0.01 per share, which would represent year-over-year growth of 50%.
It is also important to note the recent changes to analyst estimates for ZOM. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. ZOM is currently sporting a Zacks Rank of #2 (Buy).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 120, which puts it in the top 48% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zomedica Pharmaceuticals Corp. (ZOM) Gains But Lags Market: What You Should Know
In the latest trading session, Zomedica Pharmaceuticals Corp. (ZOM - Free Report) closed at $0.16, marking a +0.57% move from the previous day. This change lagged the S&P 500's 0.72% gain on the day. Meanwhile, the Dow gained 0.89%, and the Nasdaq, a tech-heavy index, added 1.47%.
Coming into today, shares of the company had lost 5.89% in the past month. In that same time, the Medical sector gained 3.7%, while the S&P 500 gained 5.85%.
Wall Street will be looking for positivity from ZOM as it approaches its next earnings report date. On that day, ZOM is projected to report earnings of -$0.01 per share, which would represent year-over-year growth of 50%.
It is also important to note the recent changes to analyst estimates for ZOM. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. ZOM is currently sporting a Zacks Rank of #2 (Buy).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 120, which puts it in the top 48% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.